Plain-English translation of NCT07047716 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing lenacapavir, a new medication given as an injection once per year, to help prevent HIV infection in people who are at risk. Researchers want to understand how safe and well-tolerated this treatment is, and how the body processes it over time. If it works, this medication could offer a simpler prevention option than daily pills.
Currently, people at risk for HIV typically take a daily preventive pill, which requires daily remembering and commitment. This study explores whether a once-yearly injection could provide the same protection with less burden, making HIV prevention more accessible and easier to stick with.
You would receive an initial injection on Day 1, along with two days of oral medication to start. Then, about one year later, you would return for a second injection. Throughout the study, researchers would monitor how the medication works in your body through blood tests and follow-up visits. The entire study lasts approximately one to two years, and you can discuss with your doctor whether to continue with additional doses or transition to monitoring as the medication leaves your system.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
United States